Endymed Ltd

Tel Aviv Stock Exchange ENDY.TA

Endymed Ltd EBITDA Margin for the year ending December 31, 2023: 6.73%

Endymed Ltd EBITDA Margin is 6.73% for the year ending December 31, 2023, a -36.20% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Endymed Ltd EBITDA Margin for the year ending December 31, 2022 was 10.54%, a -28.28% change year over year.
Endymed Ltd EBITDA Margin for the year ending December 31, 2021 was 14.70%, a 156.84% change year over year.
Endymed Ltd EBITDA Margin for the year ending December 31, 2020 was 5.72%, a -57.12% change year over year.
Endymed Ltd EBITDA Margin for the year ending December 31, 2019 was 13.35%, a 8.59% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tel Aviv Stock Exchange: ENDY.TA

Endymed Ltd

CEO	Mr. Yossi Bar-On CPA
IPO Date	July 19, 2007
Location	United States
Headquarters	4400 Route 9 South
Employees	46
Sector	Consumer Discretionary
Industries Cosmetics Pharmaceuticals

Description

Endymed Ltd, a medical technology company, designs, develops, and commercializes energy based medical aesthetic treatment systems for the professional and consumer markets worldwide. Its products comprise EndyMed PRO, a multi-application treatment platform; PURE 2.0 that offers professional skin tightening, body contouring, and functional resurfacing; and 3DEEP radiofrequency technology, a solution for the treatment of skin tightening, wrinkle reduction, body contouring, texture enhancement, cellulite reduction, circumferential reduction, acne and acne scar reduction, stretch mark reduction, RF micro needling, and fractional resurfacing. The company was founded in 2007 and is based in Freehold, New Jersey.

Key trends

Past 5 years